Most cited papers from Taustine Eye Center

Taustine Eye Center

What are the most cited papers from Taustine Eye Center?

The most cited paper from Taustine Eye Center is "A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combinati" (Coleen M. Clineschmidt, Robert Williams, Ellen Snyder et al., 1998), with 140 citations. Next come "Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension" (131) and "Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular Hypertension" (80).

Published TypeFieldAccess

Showing 26 of 26 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combinati Coleen M. Clineschmidt, Robert Williams, Ellen Snyder et al. · Ophthalmology	Oct 1998	140
2	Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension Robert D. Williams, Gary D. Novack, Thomas van Haarlem et al. · American Journal of Ophthalmology	29 Jul 2011	131
3	Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular Hypertension Earl Randy Craven, Thomas R. Walters, Robert D. Williams et al. · Journal of Ocular Pharmacology and Therapeutics	Aug 2005	80
4	Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost Robert D. Williams · Advances in Therapy	Nov 2002	53
5	Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4 Robert D. Williams, JOHN S. COHEN, Ronald L. Gross et al. · British Journal of Ophthalmology	11 Jul 2008	52
6	Increased periocular pigmentation with ocular hypotensive lipid use in African Americans Leon W. Herndon, Robert D. Williams, Martin Wand et al. · American Journal of Ophthalmology	30 Apr 2003	48
7	Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis Ian Benjamin Gaddie, Eric D. Donnenfeld, Paul M Karpecki et al. · Ophthalmology Open access	5 Jun 2023	47
8	A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma Monte S. Dirks, Robert J. Noecker, Melissa Earl et al. · Advances in Therapy	May 2006	39
9	Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH) Brandon D. Ayres, Eric D. Donnenfeld, Marjan Farid et al. · Eye Open access	24 Mar 2023	37
10	Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension Murray Fingeret, Ian Benjamin Gaddie, Marc R. Bloomenstein · Clinical and Experimental Optometry Open access	8 Jan 2019	24
11	Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye Gail L. Torkildsen, Mile Brujic, Michael Cooper et al. · Clinical ophthalmology Open access	Oct 2017	20
12	Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis Marjan Farid, Brandon D. Ayres, Eric D. Donnenfeld et al. · Clinical ophthalmology Open access	Feb 2023	16
13	Epinastine 0.05% Ophthalmic Solution in Contact Lens-Wearing Subjects With a History of Allergic Conjunctivitis Kelly Kinney Nichols, Scot Morris, Ian Benjamin Gaddie et al. · Eye & Contact Lens Science & Clinical Practice	30 Dec 2008	10
14	Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis Pinakin Gunvant Davey, Marjan Farid, Paul M Karpecki et al. · Healthcare Open access	26 Jul 2024	8
15	Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study Ehsan Sadri, James D. Paauw, Joseph B. Ciolino et al. · Cornea Open access	9 Feb 2024	8
16	A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers Paul M Karpecki, Sidney L Weiss, William G. Kramer et al. · Clinical ophthalmology Open access	Apr 2019	8
17	A Comparison of Dorzolamide/Timolol-Fixed Combination Versus Bimatoprost in Patients with Open-Angle Glaucoma Who Are Poorly Controlled on Latanoprost Elizabeth D. Sharpe, Robert D. Williams, Jeanette A. Stewart et al. · Journal of Ocular Pharmacology and Therapeutics	16 Jul 2008	6
18	Combination Low-Dose Pilocarpine/Diclofenac Sodium and Pilocarpine Alone for Presbyopia: Results of a Randomized Phase 2b Clinical Trial Marjan Farid, Sheri Rowen, Majid Moshirfar et al. · Clinical ophthalmology Open access	Nov 2024	5
19	The Demodex Expert Panel on Treatment and Eyelid Health (DEPTH) Consensus Regarding the Preferred Treatment for Demodex Blepharitis Eric D. Donnenfeld, Kelly Kinney Nichols, Brandon D. Ayres et al. · Clinical ophthalmology Open access	Jun 2025	3
20	Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review William Daniel Stamer, Thomas Y.H. Chiu, Da‐Wen Lu et al. · Frontiers in Ophthalmology ReviewOpen access	28 Mar 2025	3
21	Using Lotilaner Ophthalmic Solution, 0.25% to Treat Demodex Blepharitis in Patients Who Were Initially Misdiagnosed: A Case Series Laura M. Periman, Richard L. Lindstrom, Paul M Karpecki et al. · Clinical Optometry Open access	Jun 2026	0
22	Lotilaner ophthalmic solution 0.25% in the treatment of Demodex blepharitis: A case report Paul M Karpecki, Brandon D. Ayres, Eric Donnenfeld et al. · SAGE Open Medical Case Reports Open access	2026	0
23	Effects of Lotilaner Ophthalmic Solution, 0.25% on Demodex Blepharitis Patients with Meibomian Gland Disease Preeya Gupta, Ian Gaddie, Mitchell Shultz et al. · Clinical ophthalmology Open access	2026	0
24	Patient Preferences between two multi-purpose disinfecting solutions Milton M. Hom, I Ben Gaddie, Kirk L Smick · Investigative Ophthalmology & Visual Science	11 Jun 2015	0
25	IOP Lowering Efficacy of Bimatoprost and Latanoprost for the Treatment of Normal Tension Glaucoma Robert D. Williams, Robert J Noecker, Monte S. Dirks et al. · Investigative Ophthalmology & Visual Science	May 2005	0
26	A Comparison of Dorzolamide/Timolol Maleate Fixed Combination versus Bimatoprost in Primary Open-Angle Glaucoma Patients Who Are Insufficiently Controlled on Latanoprost William C. Stewart, Elizabeth D. Sharpe, Robert D. Williams et al. · Investigative Ophthalmology & Visual Science	10 May 2007	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.